Ann Lab Med.  2017 Nov;37(6):547-549. 10.3343/alm.2017.37.6.547.

Highly Aggressive de novo Aleukemic Variant of Mast Cell Leukemia Without KIT D816V Mutation

Affiliations
  • 1Department of Laboratory Medicine, Kyungpook National University Hospital, Daegu, Korea. suhjs@knu.ac.kr
  • 2Department of Pathology, Kyungpook National University Hospital, Daegu, Korea.
  • 3Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea.

Abstract

No abstract available.


MeSH Terms

Leukemia, Mast-Cell*
Mast Cells*

Figure

  • Fig. 1 Peripheral blood and bone marrow aspiration smear findings. (A) Peripheral blood findings show leukoerythroblastic reaction and no circulating mast cells (Wright-Giemsa stain, ×400). (B) Bone marrow aspiration finding shows atypical promastocytes, which are hypogranulated and degranulated bizarre-looking cells mostly with heavy cytoplasmic vacuoles. Characteristic features of surface projections with eccentrically positioned oval nuclei and hypogranulated cytoplasm, with focal granule accumulations with or without granule fusion are seen. Cells with bilobed and polylobed nuclei with high to low nucleus-to-cytoplasm ratio are frequently observed (Wright-Giemsa stain, ×1,000).

  • Fig. 2 Immunohistochemical staining of CD2 and CD25, which are used as markers for immature mast cells. (A) Im-munohistochemical staining shows positive CD2 staining. Bone marrow section showing multifocal and dense infiltrates of mast cells (×200). (B) High-power view of CD2 cytoplasmic staining of mast cells (×1,000). (C) Immunohistochemical staining shows negative CD25 staining (×200).


Reference

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC;2008. p. 54–63.
2. Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007; 37:435–453. PMID: 17537151.
3. Georgin-Lavialle S, Lhermitte L, Dubreuil P, Chandesris MO, Hermine O, Damaj G. Mast cell leukemia. Blood. 2013; 121:1285–1295. PMID: 23243287.
4. Valentini CG, Rondoni M, Pogliani EM, Van Lint MT, Cattaneo C, Marbello L, et al. Mast cell leukemia: a report of ten cases. Ann Hematol. 2008; 87:505–508. PMID: 18172645.
5. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009; 113:5727–5736. PMID: 19363219.
6. Noack F, Sotlar K, Notter M, Thiel E, Valent P, Horny HP. Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V. Leuk Lymphoma. 2004; 45:2295–2302. PMID: 15512820.
7. Sperr WR, Escribano L, Jordan JH, Schernthaner GH, Kundi M, Horny HP, et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res. 2001; 25:529–536. PMID: 11377677.
8. Baumgartner C, Sonneck K, Krauth MT, Kneidinger M, Födinger M, Hauswirth AW, et al. Immunohistochemical assessment of CD25 is equally sensitive and diagnostic in mastocytosis compared to flow cytometry. Eur J Clin Invest. 2008; 38:326–335. PMID: 18363719.
9. Savini P, Rondoni M, Poletti G, Lanzi A, Quercia O, Soverini S, et al. Serum total tryptase level confirms itself as a more reliable marker of mast cells burden in mast cell leukaemia (aleukaemic variant). Case Rep Hematol. 2015; 2015:737302. PMID: 25755899.
10. Theoharides TC, Valent P, Akin C. Mast Cells, Mastocytosis, and Related Disorders. N Engl J Med. 2015; 373:163–172. PMID: 26154789.
Full Text Links
  • ALM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr